Výsledky vyhledávání - "Alexey Samtsov"

Revisiting the question of cutaneous vasculitis classification

Autor: O. V Grabovskaya, Olga Yu. Olisova, Irena E. Belousova, Vladislav R. Khairutdinov, Alexey Samtsov, A. E. Karamova, A. L. Bakulev, E. V. Sokolovskiy, M. M. Kokhan

Publikováno v: Vestnik Dermatologii i Venerologii, Vol 97, Iss 4, Pp 48-59 (2021)

Currently, there is no generally accepted terminology and classification of vasculitis and vascular cutaneous disorders. In Russia there are various approaches to the classification of cutaneous vasculitis vascular lesions are classified according to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37ba508b889680e1a6b9bd1e29fe890e
https://doi.org/10.25208/vdv1258

Zobrazit plný text záznamu

Topical therapy for pyoderma

Autor: Alexey Samtsov

Publikováno v: Vestnik Dermatologii i Venerologii, Vol 96, Iss 5, Pp 59-64 (2020)

The article is of an overview nature. It provides various classifications of pyoderma and infections of the skin and soft tissues, epidemiological data on pyoderma in our country and abroad, discusses in detail local and systemic risk factors for the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0040d997a6a3f7e6ff3dd51302dafcc
https://vestnikdv.ru/jour/article/viewFile/1167/1145

Zobrazit plný text záznamu

Recommendations Russian Society of Dermatovenerologists and Cosmetologists for systemic treatment of psoriasis during the pandemic COVID-19

Autor: Vladislav R. Khairutdinov, Marianna M. Khobeish, Alexey Samtsov, E. V. Sokolovskiy, M. M. Kokhan, A. L. Bakulev, Alexey A. Kubanov, Olga Yu. Olisova

Publikováno v: Vestnik dermatologii i venerologii. 96:9-13

Below you will find the analysis of the first published data and international clinical recommendations for the systemic treatment of patients with moderate and severe psoriasis in the context of the COVID-19 pandemic in different countries (France,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e335145d1c5447206a3eb0881a0c592
https://doi.org/10.25208/vdv1129

Zobrazit plný text záznamu

ETIOPATHOGENETIC THERAPY OF INFLAMMATORY DERMATOSES

Autor: I. E. Belousova, Alexey Samtsov, V. R. Khairutdinov

Publikováno v: Vestnik Dermatologii i Venerologii, Vol 94, Iss 2, Pp 78-83 (2018)

In chronic dermatoses significantly increases the colonization of skin by bacteria and fungi, which can have a negative impact on the course of inflammatory process. Cream Candiderm is a modern combined topical drug that has anti-inflammatory, antiba

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43412803de68971603fe0794d37d0ddc
https://doi.org/10.25208/0042-4609-2018-94-2-78-83

Zobrazit plný text záznamu

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis

Autor: T. V. Korotaeva, A. E. Karamova, V. R. Khairutdinov, Alexey Samtsov, A. L. Bakulev, Antonina V. Artemeva, Alexey A. Kubanov

Publikováno v: Vestnik Dermatologii i Venerologii, Vol 0, Iss 5, Pp 52-63 (2018)

Recent studies on psoriasis confirmed that interleukin-17 (IL-17) plays a crucial role in the progression of the disease. Inhibition of this cytokine leads to significant improvement in the course of the disease. Russian biotechnology company BIOCAD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1090fdf2e0b6eb85d0c846d1935d00
https://www.vestnikdv.ru/jour/article/view/344

Zobrazit plný text záznamu

Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy

Autor: Tadeusz Robak, Robin Eisch, Jürgen C. Becker, Youn H. Kim, Susan E. Bates, Madeleine Duvic, Adam Lerner, Joel Waksman, Richard Piekarz, Sean Whittaker, Alexey Samtsov, William McCulloch

Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3987365ae405602a6f2c7c87fb57e0
https://www.ncbi.nlm.nih.gov/pubmed/28853310

Zobrazit plný text záznamu

Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma

Autor: Youn H. Kim, Adam Lerner, Alain H. Rook, Tadeusz Robak, Sunil Reddy, Joel Waksman, Ellen J. Kim, Jürgen C. Becker, Alexey Samtsov, William McCulloch, Madeleine Duvic, Sean Whittaker

Publikováno v: Leukemia & Lymphoma

Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood, viscera). Historically, in clinical trials of CTCL there has been little consist

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4137deae494a0c83255e610f1ab8bf9e
https://www.ncbi.nlm.nih.gov/pubmed/25791237

Zobrazit plný text záznamu

Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin

Autor: Sean Whittaker, Adam Lerner, Alain H. Rook, Suephy C. Chen, Jean Nichols, Joel Waksman, Youn H. Kim, Marie-France Demierre, Tadeusz Robak, Madeleine Duvic, Ellen J. Kim, Alexey Samtsov, William McCulloch

Publikováno v: Leukemialymphoma. 54(2)

Patients with cutaneous T-cell lymphoma (CTCL) frequently experience severe pruritus that can significantly impact their quality of life. Romidepsin is approved by the US Food and Drug Administration (FDA) for the treatment of patients with CTCL who

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0940e423cd93fd4cf99984725c0b23b5
https://pubmed.ncbi.nlm.nih.gov/22839723

Zobrazit plný text záznamu

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

Autor: Adam Lerner, Youn H. Kim, William McCulloch, Sunil Reddy, Madeleine Duvic, Ellen J. Kim, Tadeusz Robak, Alexey Samtsov, Jürgen C. Becker, Sean Whittaker, Alain H. Rook, Marie-France Demierre, Julia Scarisbrick

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(29)

Purpose The primary objective of this study was to confirm the efficacy of romidepsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL). Patients and Methods This international, pivotal, single-arm, open-label, phase II study was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab14e95801a9e6d166e01bdfcd243218
https://pubmed.ncbi.nlm.nih.gov/20697094

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání